Michael Adler

Title: Michael Adler - Innovator in Pharmaceutical Formulations

Introduction

Michael Adler is an inventor based in Loerrach, Germany. He is currently employed at F. Hoffmann-La Roche AG, a leading company in the pharmaceutical industry. Although he has not yet been granted any patents, his work focuses on developing innovative pharmaceutical formulations.

Latest Patent Applications

Michael Adler's latest patent applications include:

1. **Highly Concentrated Pharmaceutical Formulations** - This invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as Rituximab, Ocrelizumab, or HuMab. The formulation is designed for subcutaneous injection and includes a suitable amount of the anti-CD20 antibody, at least one hyaluronidase enzyme, a buffering agent, stabilizers, and a nonionic surfactant. Methods for preparing these formulations and their uses are also provided.

2. **Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon** - This invention provides a stable, isotonic, aqueous solution formulation comprising 0.1-0.5 mg/mL alpha-type interferon, preferably pegylated alpha-type interferon, along with an acetate buffer system, L-methionine, sodium chloride, a surfactant, and water for injection. This formulation aims to stabilize the alpha-type interferon against loss of activity.

Conclusion

Michael Adler is making significant contributions to the field of pharmaceutical formulations through his innovative applications. His work has the potential to enhance the effectiveness and stability of important therapeutic agents.